AES Highlights

touchNEUROLOGY met with Professor Mary Koenig (McGovern Medical School, UTHealth, Houston, TX, USA) to discuss the efficacy and safety findings from the phase 2 clinical study investigating oral ganaxolone for the treatment of tuberous sclerosis complex (NCT04285346). The abstract ‘Phase 2 Open-label Clinical Study Evaluating Oral Ganaxolone for the Treatment of Seizures Associated with Tuberous […]

It was a great pleasure to meet with both Dr Monica Ferrer Socorro (NYU Langone Health, New York City, NY, USA) and Prof. Jacqueline French (NYU Grossman School of Medicine, New York City, NY, USA) to discuss a retrospective analysis investigating focal epilepsy, its clinical presentation in adolescents, highlighting disproportionate delay to diagnosis experienced by […]

touchNEUROLOGY met with Prof. Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss a subgroup analysis from a phase 3 safety study investigating the use of diazepam nasal spray in patients with seizure clusters concomitantly receiving clobazam. Diazepam nasal spray is an FDA-approved nasal spray version of diazepam, indicated for the treatment of acute, […]

We had the pleasure of meeting with Dr William E. Rosenfeld, MD (Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, MO, USA). Dr Rosenfeld discusses the use of cenobamate as an antiseizure medication for the treatment of adults with focal seizures. Here he discusses a number of posters presented at AES 2021 from […]

In conjunction with the American Epilepsy Society (AES), we had the great pleasure of meeting with Barbara Jobst (Chair, Council of Education, American Epilepsy Society, USA) to discuss the Disrupting Disparities project which aims to improve outcomes for underserved people with epilepsy (PWE) by improving the epilepsy clinical knowledge of the non-specialist epilepsy care workforce, […]

It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]

We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]

We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]